This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): W. Andrew Owens Permission Requests Google Scholar Articles by Turley, A. J. Articles by de Belder, M. A. PubMed PubMed Citation Articles by Turley, A. J. Articles by de Belder, M. A. Related Collections Education Cardiac - pharmacology Congestive Heart Failure Coronary disease

Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: the need for targeted follow-up

Department of Cardiology and Cardiothoracic Surgery, James Cook University Hospital, Marton Road, Middlesbrough, TS4 3BW, UK

*Corresponding author. Tel.: +44 1642 854623; fax: +44 1642 854190.

E-mail address: a.turley{at}btopenworld.com (A.J. Turley).

A focused review of secondary preventive medication following revascularisation provides an opportunity to ensure optimal use of these agents. A retrospective analysis of our in-house cardiothoracic surgical database was performed to identify patients undergoing non-emergency, elective surgical revascularisation discharged on four secondary preventive medications: aspirin; beta-blockers; ACE-inhibitors and statins. Of 2749 patients studied, 2302 underwent isolated coronary artery bypass grafting (CABG), mean age 65.5 years (S.D. 9.15). Overall, 2536 (92%) patients were prescribed aspirin. Beta-blockers were prescribed in 2171 (79%) patients overall, in 1096/1360 (81%) of patients with a history of myocardial infarction and in 465/619 (75%) of patients with left ventricular systolic dysfunction (LVSD). Overall, 1518 (55%) patients were prescribed an ACE-inhibitor and 179 (6.5%) an angiotensin receptor blocker (ARB); one of these agents was prescribed in 446/619 (72%) patients with LVSD and 915/1360 (67%) patients with a history of previous myocardial infarction. Overall, 2518 (92%) patients were prescribed a statin. Secondary preventive therapies are prescribed more commonly on discharge after CABG than in previous studies, but there is a continuing under-utilisation of ACE-inhibitors. To maximise the potential benefits of these agents, further study is required to understand why they are not prescribed.

Key Words: Coronary artery disease; Coronary artery bypass grafting; Secondary prevention; Angiotensin converting enzyme inhibitors; Statins